Cargando…
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
Health care spending in Italy is high and continues to increase; assessing the long-term health and economic outcomes of new therapies is essential. Atopic dermatitis (AD) is a chronic, pruritic, immune-mediated inflammatory dermatosis, a clinical condition that significantly affects patients'...
Autores principales: | Ferrari, Marco, Donadu, Matthew G., Biondi, Gabriele, Saderi, Laura, Sucato, Federica, Montesu, Maria A., Ruggiu, Paola, Merella, Paola, Chessa, Carla, Sias, Angela, Carmelita, Gabriella, Mazzarello, Vittorio, Sotgiu, Giovanni, Rosanna, Satta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946764/ https://www.ncbi.nlm.nih.gov/pubmed/36846564 http://dx.doi.org/10.1155/2023/4592087 |
Ejemplares similares
-
Blood Cells Count Derived Inflammation Indexes as Predictors of Early Treatment Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Zinellu, Angelo, et al.
Publicado: (2023) -
Impact of Sars‐CoV‐2 pandemic on psoriatic patients
por: Biondi, Gabriele, et al.
Publicado: (2022) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)